Nrf2: key target for the treatment of neurodegenerative diseases

Neurodegenerative diseases (NDDs) are predicted to be the biggest health concern in this century and the second leading cause of death by 2050. Aging population in Western societies is increasing, thus, the prevalence of these diseases is augmenting exponentially. Despite the great efforts to find a cure, current treatments remain ineffective or have low efficacy. Increasing lines of evidence point to exacerbated oxidative stress, mitochondrial dysfunction and chronic neuroinflammation as common pathological mechanisms underlying neurodegeneration. We will address the role of the nuclear factor E2-related factor 2 (Nrf2) as a potential target for the treatment of NDDs. The Nrf2-ARE pathway is an intrinsic mechanism of defence against oxidative stress. Nrf2 is a transcription factor that induces the expression of a great number of cytoprotective and detoxificant genes. There are many evidences that highlight the protective role of the Nrf2-ARE pathway in neurodegenerative conditions, as it reduces oxidative stress and neuroinflammation. Therefore, the Nrf2 pathway is being increasingly considered a therapeutic target for NDDs.

Autorentext

Ingeniero de Telecomunicaciones y Doctor en Ingeniería Industrial con 20 años de experiencia en el sector de TI, habiendo trabajado en empresas multinacionales y con larga experiencia docente como Profesor Asociado.J. Javier Rainer, Doctor Ingeniero Industrial, por la UPM. Responsable de Investigación BVBS.Ramón Galán, Catedrático de la UPM.